AAM Sees Extended Support For BIOSIM Act
Multiple US Organizations Come Together To Back Add-On Payment For Biosimilars
US representatives Kurt Schrader and Adam Kinzinger have introduced the BIOSIM Act to improve access and realize the full potential of biosimilars by encouraging an additional payment for providers when they use a biosimilar cheaper than the reference biologic. AAM and a group of organizations have extended support to the bipartisan bill.
You may also be interested in...
Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”